The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

AI isn’t neutral in women’s health. It involves learning from visibility gaps shaped by brand safety, search authority, and ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

The Arts Council of Princeton (ACP) has announced a three-person exhibition, “Divergent Forms,” featuring the work of artists ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies ...

XOMA Royalty (XOMA) and Takeda (TAK) stock in focus as the companies ink a new royalty deal and armed an existing agreement.

Clear Street analyst Tim Moore just upgraded Plug Power stock to buy. He cut his price target on the fuel cell stock, however ...